after joining the study, you provide written consent and allow the study team to review your medical history related to hereditary angioedema.

the study staff records baseline information, including the number of previous attacks and any current medications.

a comprehensive medical evaluation is performed, which may include physical examination, laboratory tests, and documentation of your current health status.

the information collected serves as a reference point for later comparisons during the study.

you receive an injection of adx-324 or, if assigned to the control group, an injection of sterile normal saline (0.9% sodium chloride solution).

the injection is given subcutaneously, meaning it is placed just under the skin.

the specified dose of adx-324 is 00 mg, delivered as a solution for injection.

after the injection, you remain in the clinic for a short observation period, typically about thirty minutes, so that any immediate reactions can be identified and treated promptly.

you attend regular clinic visits according to the study schedule, which continue throughout the extension period that runs from august 2026 to april 2030.

at each visit, safety assessments are performed, including checks for adverse events and laboratory testing.

you also record any hereditary angioedema attacks that occur between visits.

at each scheduled visit, you receive another subcutaneous injection of adx-324 (or sterile normal saline if you are in the control group) at the same dose of 00 mg.

this repeat dosing continues for the duration of the extension study, providing long‑term exposure to the medication.

throughout the study, you are asked to report any side effects, new symptoms, or changes in health status to the study staff.

regular laboratory tests and clinical evaluations help the investigators assess the long‑term safety of repeat dosing.

at the end of the study period in april 2030, a final visit is scheduled.

comprehensive assessments are performed, including a summary of all recorded hereditary angioedema attacks and any adverse events that occurred.

all study data are collected and the participant’s involvement in the trial concludes.